Will the FDA approve intismeran autogene (V940/mRNA-4157)?
intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanomaScience
Will the FDA approve intismeran autogene (V940/mRNA-4157)?
intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanomaScience
Kalshi 活跃 5 个市场·95¢ Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jul 1, 2028?·$0 总交易量·-- 流动性·-- OI
4mo·Apr 8, 2027
追踪你的预测市场持仓
连接你的 Kalshi 账户，追踪你的合约、盈亏和结算。
较大价差
暂无图表数据
市场
5(V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment completely resected stage IIB-IV melanoma before Jul 2028
$0 vol
(V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment completely resected stage IIB-IV melanoma before Jan 2028
$0 vol
(V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment completely resected stage IIB-IV melanoma before Oct 2027
$0 vol
(V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment completely resected stage IIB-IV melanoma before Jul 2027
$0 vol
(V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment completely resected stage IIB-IV melanoma before Apr 2027
$0 vol
(V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment completely resected stage IIB-IV melanoma before Jul 2028
暂无订单簿数据
If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing before Apr 1, 2027, then the market resolves to Yes.
追踪您在 Kalshi 上的投注——以及一切其他资产
从您的 Kalshi 头寸、盈亏和实时赔率开始，创建免费投资组合。然后添加加密钱包、交易所、DeFi 等——一切尽在一处。
Polymarket
Kalshi
50+ Chains
40+ Exchanges
DeFi
NFTs
16K+ Tokens
100% 免费· 只读· 加密保护